Join Our Crew

Associate Scientist, Molecular Biology

About the Position

This is a bench scientist position, reporting to the Associate Principal Scientist, Molecular Biology. The Molecular Biologist, under supervision, will aid in new assay development using Luminex platform, as well as support lentivirus production (LV). The work entails the design and assembly of complex molecular constructs, the production of plasmid stocks and the use of mammalian cell systems to produce and purify high titer lentivirus. The candidate will also engage in characterizing peptides and proteins, perform ELISAs (Luminex™), and other assays as needed.  The position offers growths into additional areas such as cell biology and molecular biology, immunology, and cell therapy. The position involves both technical and operational responsibilities.

Responsibilities Include

  • Molecular Cloning - Experience with restriction digest and TA TOPO based cloning, DNA gel electrophoresis, and bacterial transformation.
  • Set-up, validate and execute Luminex based assays.
  • Harvesting and purification of virus from mammalian cultures.
  • Maintain highest level of integrity and awareness in handling critical QC and molecular design work.
  • Actively contribute to process improvements, implement new techniques and innovative trends.
  • Manage multiple internal projects from R&D, Quality, Analytical, and Manufacturing Sciences and collaborate with external sources.
  • Show a high level of flexibility in supporting various other activities and be ready to learn new techniques outside of existing field of expertise.
  • Perform lab associated tasks in accordance with cGLP and Cabaletta Bio lab safety policies
  • Maintain accurate and well-organized records and electronic laboratory notebook

Required Qualifications

  • BSc or MS degree in Biology (or closely related field) or 2-5 years of experience.
  • Hands on experience with molecular biology techniques
  • Experience with cell culture (aseptic technique) and molecular biology is required.
  • Experience in a startup industrial setting highly desirable.
  • General lab skills; including sterile technique, human tissue handling.
  • Must be highly organized and able to work independently.
  • Prior work experience in matrix managed organizations and ability to work in a team-oriented culture.
  • Must be able to clearly communicate in writing, must have a desire to be part of a growing organization that uses cutting-edge science.
  • Strong team orientation and passion for continuous self-development
  • A high level of flexibility to support various other activities the ability to learn new techniques outside of existing field of expertise

Preferred Skills

  • Tangential Flow Filtration (TFF), flow cytometry.

How to Apply

Please email directly to submit an application.

Please include your CV along with the title of the position you are applying for.


Our most important asset is our people and we offer competitive benefits including health and retirement, PTO, and stock option plans.

Equal Opportunity Employer

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.

About Cabaletta Bio

Cabaletta Bio (NASDAQ: CABA) is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-expressing B cells while sparing normal antibody-expressing B cells, which are essential for human health. Cabaletta’s Approach for selective B cell Ablation platform, called our CABA™ platform, has applicability across more than two dozen B cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. CAAR T technology is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop CAAR T technology to treat B cell-mediated autoimmune diseases.

The Company’s lead product candidate, DSG3-CAART, received IND clearance from the FDA in September 2019, and initial safety data in clinical trials has been reported. DSG3-CAART is designed to be a potential treatment for patients with mucosal pemphigus vulgaris (mPV), which is a rare autoimmune blistering disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. Cabaletta Bio is also pursuing additional pipeline candidates for other B cell mediated disorders including MuSK Myasthenia Gravis (MG) with an IND planned for 2H 2021, mucocutaneous PV, PLA2R positive membranous nephropathy (PMN), and Factor VIII inhibitors.

Uniquely Differentiated. Rapid. Elegant.

At Cabaletta, we are driven by the shared mission of developing a new type of therapy, where patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that success in the Cabaletta mission lies in the hands of individuals across every aspect of the company. To nurture this, we make an active commitment to the well-being and continuous growth of each person who joins our team. In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew